Enhanced HIV-1 neutralization by antibody heteroligation - Wikidata - wikimedia - TriplyDB

Enhanced HIV-1 neutralization by antibody heteroligation

Enhanced HIV-1 neutralization by antibody heteroligation

http://www.wikidata.org/entity/Q35735385

about

Structural insights on the role of antibodies in HIV-1 vaccine and therapy Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail Redemption of autoreactive B cells.Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast HIV takes double hit before entry Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.Polyreactivity and autoreactivity among HIV-1 antibodies.Cross-reactive broadly neutralizing antibodies: timing is everything.Antigen-driven induction of polyreactive IgM during intracellular bacterial infection.Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.Delineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Candidate antibody-based therapeutics against HIV-1.Improved outlook on HIV-1 prevention and vaccine development.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?Bispecific antibodies for viral immunotherapy.Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries.Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity.

P2860

Q26829461-40820D76-8A58-487E-9E8F-1E1B3AE008EB Q26852927-5858A229-9C7F-4061-A7D3-CB1AB26A0280 Q27676864-62BB1C93-5A05-42AB-AF64-9A6CA241D779 Q28728917-3173A672-4DED-428F-ABF8-BE8AA1BFC609 Q30524110-FD9CE6BC-692E-4AD5-A444-D6367BE9893A Q33835034-62C8AD11-262D-40FB-A005-A953A049EE8D Q33922778-43808157-A88F-4130-AC77-90BAAAAAA70A Q34324992-A8F8A009-FAAD-412F-BDAE-BC7DFF577E62 Q34412302-AFCB5C81-311B-4E4C-8402-53C2610DA71E Q34480254-63DB5E42-9F22-4B73-B952-6B5BDA6935B3 Q34502641-5DC8C229-3D43-4AB2-B635-E23F1D09AF29 Q34531219-20D668AD-FF57-4D6E-9751-98592FDB0CA7 Q34992787-3293E808-65BA-4FA8-BBE3-2D6E521B2BA9 Q36105782-5FD8EEF0-4622-4928-B58C-1F53D91C30FF Q36106473-7034C9DB-7EE8-44C2-AE75-6C409FC1D68E Q36506821-6FCA738C-91C4-4B24-A5BF-E69D368D5720 Q37086915-019A3B09-C5A7-492A-ADA7-89095BF9C4A7 Q37621530-3EBEFBA4-31A7-44A9-B2AF-8BBFBA9BEA64 Q37998496-950E6D7E-784E-4FF3-ABDD-02CB11B394DC Q38009870-1CA558E0-820A-43BD-B7AA-FB922604F327 Q38038410-82B0F49B-9C56-47BD-8955-1F6139AFC29D Q38618790-4006F866-E6E4-4A57-B32A-BB3B5AA36513 Q38717198-F9F3847F-177C-4A64-8C85-31D20DCC4C08 Q38804059-9D573F54-7FFF-4963-AB82-BDD9684E8D6C Q38992408-B5C49917-0680-4A53-9FAF-ED6B22571461 Q39261383-9A56568D-1DE7-43D6-B614-194AB27301CE Q40159913-F9581135-9CDD-4413-A205-666D9FCA91CD Q42270590-2FB30A1E-F9AD-4520-9132-FE5038A4F5BB Q52653118-A7A82111-FF1D-4030-AC63-BBA252BC752F Q52692811-FBC0DEF5-C14D-4EE6-93A7-25727335BD92 Q55265892-7B8C25F6-D5A2-4D10-9DA5-8FB26907B79B

P2860

Enhanced HIV-1 neutralization by antibody heteroligation

http://www.wikidata.org/entity/Q35735385

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Enhanced HIV-1 neutralization by antibody heteroligation

@ast

Enhanced HIV-1 neutralization by antibody heteroligation

@en

type

label

Enhanced HIV-1 neutralization by antibody heteroligation

@ast

Enhanced HIV-1 neutralization by antibody heteroligation

@en

prefLabel

Enhanced HIV-1 neutralization by antibody heteroligation

@ast

Enhanced HIV-1 neutralization by antibody heteroligation

@en

P1433

Q35735385-E3E8AA67-5F55-4F28-8FC9-354384D98484

P1476

Q35735385-0213217C-FB3A-42BD-A89E-117EBDB15F64

P2093

Q35735385-080BC95A-0013-42AD-BA1F-AD9393F3FC43

Q35735385-1CBCFDA5-C930-4437-B713-A4F6DD36C5D5

Q35735385-3C925EBB-2464-4F57-87CC-79951600ACAC

Q35735385-E670D2B6-BD70-44CA-98A7-4C7AF204417E

P2860

Q35735385-00B63DEA-2722-40B5-861A-94DF517D1443

Q35735385-0126C94C-E1BB-4384-BB64-0171EBF10C39

Q35735385-03A065C3-45D5-47EB-A96C-E08FBFF59279

Q35735385-043A6FEC-2E9C-4FB3-98D6-75D86BF1444D

Q35735385-045584AC-4CB5-4865-984F-648B5E1D8C3E

Q35735385-0A098B78-E642-4509-804B-731294EFA9E8

Q35735385-0B6E49CB-E247-4C41-B1C2-DBCAFD293B32

Q35735385-0DF4A9C9-7A53-450F-8FB8-2D3FD45361A7

Q35735385-0EA241B5-CD6A-41F6-8113-976F3216301A

Q35735385-0F0F133F-EF2A-481F-81DE-D9A52AABFF45

P304

Q35735385-0BDE313B-1077-4C08-A98F-BDEAA9DFFA86

P31

Q35735385-27B89E2A-8FC9-43F6-A847-5FFFF3289FF3

P356

Q35735385-D455A067-6F50-43AC-A631-DC990FB04B05

P407

Q35735385-C6388D9B-9908-4408-95DB-352E90276CF2

P433

Q35735385-4BE834DB-54BD-4ED5-83D7-CA70AA729ACA

P478

Q35735385-2032B3EE-DBFD-4B54-A9B7-4E8DEDDB51AA

P50

Q35735385-4CE14C0B-7AEB-415E-A492-11805C83D809

P577

Q35735385-A27225C8-BA5C-47DE-AA95-8E228D0EAD20

P5875

Q35735385-EE23CEFF-74DB-43DE-9B0F-2F061FEBA499

P698

Q35735385-A68FBB33-C3A4-4A42-9012-F01473F84E99

P932

Q35735385-569174CD-9FF4-4FCB-8297-26279E01E06C

P356

PNAS.1120059109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Enhanced HIV-1 neutralization by antibody heteroligation

@en

P2093

Hugo Mouquet

http://www.w3.org/2001/XMLSchema#string

Johannes F Scheid

http://www.w3.org/2001/XMLSchema#string

Malte Warncke

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

P2860

Few and far between: how HIV may be evading antibody avidity

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

Antibody neutralization and escape by HIV-1

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

P304

875-880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1120059109

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Michel C. Nussenzweig

P577

2012-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51984051

http://www.w3.org/2001/XMLSchema#string

P698

22219363

http://www.w3.org/2001/XMLSchema#string

P932

3271928

http://www.w3.org/2001/XMLSchema#string